The Valley Desk

NCT06325683 · Interventional trial

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Overall registry status Suspended

Phase 2

Conditions Progressive Glioblastoma, Recurrent Glioblastoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov